Boosting influenza vaccine responses in the elderly using a brief bout of exercise
Not Applicable
- Conditions
- Advanced ageInfluenza vaccine responsesInflammatory and Immune System - Normal development and function of the immune system
- Registration Number
- ACTRN12611001119987
- Lead Sponsor
- niversity of Sydney
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Stopped early
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
Aged 65 years or older.
Exclusion Criteria
History of vaccine related allergies or side-effects; allergy to any constituent of the vaccine (including eggs and chicken); current immune disorder (including rheumatoid arthritis and asthma) or acute infection; current steroid or anticoagulant medication, any joint injury or pain which restricts completion of the exercise task, or recent history (6 months prior) of strength training
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link acute weight-lifting exercise to enhanced influenza vaccine responses in elderly populations?
How does pre-vaccination exercise compare to standard-of-care approaches in improving seroconversion rates for influenza vaccines in immunosenescent individuals?
Which biomarkers correlate with improved antibody titers following exercise-induced immune modulation prior to influenza vaccination in older adults?
What are the potential adverse events associated with acute resistance exercise in elderly patients receiving influenza vaccines, and how are they managed?
How do cytokine profiles and T-cell activation patterns in ACTRN12611001119987 relate to other immune-boosting interventions for vaccines in aging populations?